Gsa Capital Partners LLP Axsome Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$36.06 - $69.85 $393,630 - $762,482	10,916 New	10,916 $487,000
Q2 2022 Aug 09, 2022	SELL	$21.74 - $46.75 $405,581 - $872,168	-18,656 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$23.7 - $41.39 $253,566 - $442,831	10,699 Added 134.46%	18,656 $772,000
Q4 2021 Feb 14, 2022	BUY	$30.7 - $43.36 $244,279 - $345,015	7,957 New	7,957 $301,000
Q3 2021 Nov 12, 2021	SELL	$19.91 - $68.26 $186,477 - $639,323	-9,366 Closed	0 $0

Q2 2021 Aug 05, 2021	BUY	$50.63 - $73.5 $474,200 - $688,401	9,366 New	9,366 $632,000

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.